Workflow
Bohui Innovation(300318)
icon
Search documents
生物制品板块短线拉升,天坛生物涨停
Xin Lang Cai Jing· 2025-08-04 06:01
Group 1 - The biopharmaceutical sector experienced a short-term surge, with TianTan Bio reaching the daily limit increase [1] - WanZe Co. previously hit the limit up, indicating strong market interest [1] - Other companies such as Aidi Pharmaceutical, ZhiFei Biological, BoYa Bio, BoHui Innovation, and PaiLin Bio also saw significant gains [1]
生物制品上市公司董秘PK:博晖创新董海锋成行业“劳模” 年接待投资者1500次排名第一
Xin Lang Zheng Quan· 2025-08-01 05:27
专题:专题|2024年度A股董秘数据报告:1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁",在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示,2024年A股上市公司董秘薪酬合计达40.86亿元,平均年薪75.43万元。 分行业来看,统计数据显示,A股共有54家上市生物制品公司,董事会秘书聘任总体情况如下(部分统 计口径剔除无效数据)。 从董秘的年龄分布来看,介于40岁-50岁的董秘是市场的中坚力量,占比达到61%;50岁以上的董秘占 比为15%;30岁-40岁的董秘占比为18%;小于或等于30岁的董秘占比为6%。其中,最年轻的上市公司 董秘年仅28岁,为康乐卫士的任恩奇。 年薪最低的五名董秘分别为华兰疫苗的路珂、*ST四环(维权)的周扬、康乐卫士的任恩奇、赛升药业 的王雪峰、近岸蛋白的王笃强,年薪分别为23.9万元、33.34万元、38.32万元、39.48万元、46.08万元。 从任职年限看,上述五名董秘分别于公司任职不满1年、不满1年、1年、14年、4年。 从接待投资者次数看,各上市公司接待情况差异较大。经统计,年接待次数小于10次的公司数量 ...
生物制品上市公司董秘PK:辽宁成大邱闯成为业内唯一博士董秘 今年5月刚刚上任
Xin Lang Zheng Quan· 2025-08-01 05:24
Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for secretaries in the A-share biopharmaceutical sector is 1.01 million yuan [5] - The distribution of salaries is as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] Age and Education Distribution - The age distribution of secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those aged 30-40 make up 18% [1] - In terms of education, 52% of secretaries hold a bachelor's degree, while 44% have a master's degree, and only 2% possess a doctoral degree [3] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [7] - The top five companies with the highest number of investor meetings are: Bohui Innovation (1,500 meetings), Jindike (777 meetings), Nearshore Protein (681 meetings), Sailun Biotech (549 meetings), and Kanghua Biotech (504 meetings) [9]
生物制品上市公司董秘PK:康乐卫士任恩奇为行业最年轻董秘 任职已满1年年薪38.32万元
Xin Lang Zheng Quan· 2025-08-01 05:20
Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]
医药上市公司董秘PK:三诺生物郑霁耘成行业“劳模” 年接待投资者2661次排名第一
Xin Lang Zheng Quan· 2025-08-01 04:47
Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]
医药上市公司董秘PK:益方生物江岳恒年薪520.65万元行业第二 已在公司任职5年
Xin Lang Zheng Quan· 2025-08-01 04:45
Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]
A股生物制品板块午后拉升,智飞生物涨超14%,沃森生物涨超12%,康泰生物、三元基因、博晖创新、百克生物、智翔金泰等跟涨。
news flash· 2025-07-24 05:20
Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]
博晖创新: 第八届监事会第十一次会议决议公告
Zheng Quan Zhi Xing· 2025-06-27 16:23
Group 1 - The company held its 11th meeting of the 8th Supervisory Board on June 27, 2025, with all three supervisors present, complying with legal and procedural requirements [1][2] - The Supervisory Board approved a proposal allowing the company and its subsidiaries to borrow up to RMB 1 billion from the related party, Wuhai Junzheng Technology Industry Group Co., Ltd., to meet operational needs and improve financing efficiency [1][2] - The borrowing will be at a rate not exceeding the People's Bank of China’s loan market quotation rate, without the need for guarantees or collateral, and will be used for daily operations, project construction, and other funding needs [1][2] Group 2 - The Supervisory Board concluded that borrowing from Junzheng Technology would meet the company's operational development needs, reduce financing costs, and maintain the interests of all shareholders without violating any laws or regulations [2] - The voting result for the proposal was unanimous, with 2 votes in favor and no opposition or abstentions, representing 100% of the total votes [2]
博晖创新(300318) - 关于公司向关联方借款暨关联交易的公告
2025-06-27 10:15
证券代码:300318 证券简称:博晖创新 公告编号:临 2025-029 北京博晖创新生物技术集团股份有限公司 关于公司向关联方借款暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新") 于 2025 年 6 月 27 日召开第八届董事会第十二次会议、第八届监事会第十一次会 议,审议通过了《关于公司向关联方借款暨关联交易的议案》,现就相关事项公 告如下: 一、关联交易概述 为满足生产经营需求,提高融资效率,公司及合并范围内各下属公司可根据 各自经营需要向关联方乌海市君正科技产业集团有限责任公司(以下简称"君正 科技")申请借款,借款额度不超过人民币10亿元。公司及合并范围内各下属公 司可根据实际需要在借款额度内分批次循环使用。借款利率不高于中国人民银行 规定的贷款市场报价利率,无需提供保证、抵押、质押等任何形式的担保。上述 借款将用于日常经营、项目建设及其他资金需求。 君正科技为公司实际控制人杜江涛先生控制的企业,根据《深圳证券交易所 创业板股票上市规则》的相关规定,本次交易构 ...
博晖创新(300318) - 第八届监事会第十一次会议决议公告
2025-06-27 10:15
证券代码:300318 证券简称:博晖创新 公告编号:临 2025-028 北京博晖创新生物技术集团股份有限公司 北京博晖创新生物技术集团股份有限公司(以下简称"公司"或"博晖创新")第 八届监事会第十一次会议于 2025 年 6 月 27 日在公司会议室召开,会议通知于 2025 年 6 月 16 日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司 监事会主席杜江虹女士主持,会议采取现场和通讯表决相结合方式进行,本次会议 应出席监事 3 人,实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和 《公司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案: 1、审议通过《关于公司向关联方借款暨关联交易的议案》 为满足生产经营需求,提高融资效率,公司及合并范围内各下属公司可根据各 自经营需要向关联方乌海市君正科技产业集团有限责任公司申请借款,借款额度不 超过人民币 10 亿元。公司及合并范围内各下属公司可根据实际需要在借款额度内 分批次循环使用。借款利率不高于中国人民银行规定的贷款市场报价利率,无需提 供保证、抵押、质押等任何形式的担保。上述借款将用于日常经营、项目建设及其 ...